If a company builds assets at 27.8% a year, faster than its revenue growth rate of 13.8% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Swedish Orphan Biovitrum AB's average Total Assets Growth Rate was 37.80% per year.
During the past 3 years, the average Total Assets Growth Rate was 15.20% per year.
During the past 5 years, the average Total Assets Growth Rate was 27.80% per year.
During the past 10 years, the average Total Assets Growth Rate was 33.20% per year.
During the past 13 years, Swedish Orphan Biovitrum AB's highest 3-Year average Total Assets Growth Rate was 80.90%. The lowest was -19.50%. And the median was 15.20%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB (OTCPK:BIOVF) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Swedish Orphan Biovitrum AB's Asset Turnover for the quarter that ended in Mar. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Swedish Orphan Biovitrum AB Total Assets Related Terms
Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Swedish Orphan Biovitrum AB (Swedish Orphan Biovitrum AB) Business Description
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
Swedish Orphan Biovitrum AB (Swedish Orphan Biovitrum AB) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BIOVF has been successfully added to your 